Study on the efficacy and safety of Xuezhikang combined with PCSK9 inhibitor in the treatment of coronary heart disease
10.3969/j.issn.1671-8348.2025.07.006
- VernacularTitle:血脂康联合PCSK9抑制剂治疗冠心病的临床效果及安全性
- Author:
Ziming LIU
1
;
Xiaozai HE
;
Hong ZENG
;
Jing WANG
;
Yuan HUANG
;
Zhitang CHANG
Author Information
1. 江西省人民医院(南昌医学院第一附属医院)心血管内科,南昌 330000
- Keywords:
coronary heart disease;
PCSK9 inhibitor;
Xuezhikang;
low-density lipoprotein cholesterol;
major adverse cardiovascular events
- From:
Chongqing Medicine
2025;54(7):1560-1565
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the lipid-lowering efficacy and safety of Xuezhikang combined with PCSK9 inhibitor in patients with coronary heart disease.Methods A total of 102 patients with coronary heart disease hospitalized in Jiangxi Provincial People's Hospital from June 2023 to November 2024 were enrolled in this study and randomly divided into a control group(50 cases)and an experimental group(52 cases).The control group received basic medication for secondary prevention of coronary heart disease,while the experi-mental group received Xuezhikang combined with PCSK9 inhibitor in addition to the basic medication.After 6 months of treatment,blood lipid indicators,liver function indicators,kidney function indicators,incidence of major adverse cardiovascular events(MACE),and incidence of adverse drug reactions were observed.Results After treatment,LDL-C,TC,AST,and ALT levels decreased in both groups compared with before treatment.The experimental group showed significantly lower levels of these indicators than the control group,with statistically significant differences(P<0.05).Both groups had one case of adverse drug reaction each,showing no statistically significant difference(P>0.05).The MACE incidence was higher in the control group than in the experimental group(18.0%vs.3.8%,P<0.05).The lipid goal achievement rate was low-er in the control group than in the experimental group(44.0%vs.73.1%,P<0.05).Conclusion The com-bination of Xuezhikang and PCSK9 inhibitors demonstrates definite clinical efficacy in coronary heart disease patients,reduces MACE risk,and improves lipid goal achievement rates.
